PD-1+Tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer

Cancer Immunology Research

Volumn 3, Issue 6, 2015, Pages 620-630

  Severson, Jill J ^a   Serracino, Hilary S ^a   Mateescu, Valerica ^a   Raeburn, Christopher D ^b,c   McIntyre, Robert C ^b,c   Sams, Sharon B ^a,c   Haugen, Bryan R ^a,c   French, Jena D ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45RO ANTIGEN; CD69 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ECALECTIN; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; IONOMYCIN; KI 67 ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIFFERENTIATED THYROID CANCER; DOWN REGULATION; EXHAUSTION; EXOCYTOSIS; FEMALE; FLOW CYTOMETRY; FUNCTIONAL STATUS; HUMAN; HUMAN TISSUE; MALE; MEMORY CELL; MIDDLE AGED; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; YOUNG ADULT; BIOSYNTHESIS; CANCER GRADING; CANCER STAGING; CYTOTOXICITY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; METABOLISM; METASTASIS; PATHOLOGY; RECURRENT DISEASE; THYROID TUMOR;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; RECURRENCE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84962019348     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0201     Document Type: Article

References (39)

1. Howlader N, NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, et al. (eds). Surveillance Epidemiology and End Results (SEER): Cancer Statistics Review 1975-2008. Bethesda, MD: National Cancer Institute; 2011. Available from: http://seer.cancer.gov/csr/1975-2008.
2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
3. Ito Y, Jikuzono T, Higashiyama T, Asahi S, Tomoda C, Takamura Y, et al. Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. World J Surg 2006;30:1821-8.
4. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC Jr, Klopper JP, et al. Programmed death-1+ T cells and regulatory Tcells are enriched in tumorinvolved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab 2012;97:E934-43.
5. Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492-9.
6. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003;77:4911-27.
7. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007;27:670-84.
8. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537-44.
9. Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustionoftumor-specificCD8 (+) Tcellsinmetastases frommelanoma patients. J Clin Invest 2011;121:2350-60.
10. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175-86.
11. + T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012;72:887-96.
12. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010;107:7875-80.
13. Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013;121:1612-21.
14. Wang SF, Fouquet S, Chapon M, Salmon H, Regnier F, Labroquere K, et al. Early T cell signalling isreversibly altered in PD-1Tlymphocytes infiltrating human tumors. PLoS ONE 2011;6:e17621.
15. + T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7:389-95.
16. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004;64:2865-73.
17. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012;122:1271-82.
18. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10:29-37.
19. Brooks DG, Teyton L, Oldstone MB, McGavern DB. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J Virol 2005;79:10514-27.
20. Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE, et al. Molecular and transcriptional basis of CD4 (+) T cell dysfunction during chronic infection. Immunity 2014;40:289-302.
21. + T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol 2010;185:3007-18.
22. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007;8:1246-54.
23. + T cells during recurrence of melanoma. J Immunol 2013;190:4899-909.
24. Phillips T, Murray G, Wakamiya K, Askaa J, Huang D, Welcher R, et al. Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol 2007;15:325-31.
25. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
26. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
27. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
28. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006;203:883-95.
29. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6:1245-52.
30. + Tregs. J Clin Invest 2012;122:2395-404.
31. + resting regulatory T cells from activated T cells. J Immunol 2006;176:2808-16.
32. Jin HT, Jeong YH, Park HJ, Ha SJ. Mechanism of T cell exhaustion in a chronic environment. BMB Rep 2011;44:217-31.
33. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128-38.
34. Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 2011;3:111ra120.
35. + regulatory T-cell activitytosuppress alloimmune responses. Transplantation 2007;83:774-82.
36. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
37. Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 2011;17:2270-80.
38. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
39. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28.